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Background: In developing countries, the treatment of hemophilia patients with inhibitors is 
presently the most challenging and serious issue in hemophilia management, direct costs of 
clotting factor concentrates accounting for .98% of the highest economic burden absorbed for 
the health care of patients in this setting. In the setting of chronic diseases, cost-utility analysis, 
which takes into account the beneficial effects of a given treatment/health care intervention in 
terms of health-related quality of life, is likely to be the most appropriate approach.
Objective: The aim of this study was to assess the incremental cost-effectiveness ratios of 
immune tolerance induction (ITI) therapy with plasma-derived factor VIII concentrates versus 
on-demand treatment with recombinant-activated FVIIa (rFVIIa) in hemophilia A with high 
titer inhibitors from an Iranian Ministry of Health perspective.
Methods: This study was based on the study of Knight et al, which evaluated the cost-
  effectiveness ratios of different treatments for hemophilia A with high-responding inhibitors. 
To adapt Knight et al’s results to the Iranian context, a few clinical parameters were varied, 
and cost data were replaced with the corresponding Iranian estimates of resource use. The time 
horizon of the analysis was 10 years. One-way sensitivity analyses were performed,   varying 
the cost of the clotting factor, the drug dose, and the administration frequency, to test the 
  robustness of the analysis.
Results: Comparison of the incremental cost-effectiveness ratios between the three ITI 
  protocols and the on-demand regimen with rFVIIa shows that all three ITI protocols dominate 
the on-demand regimen with rFVIIa. Between the ITI protocols the low-dose ITI protocol 
dominates both the Bonn ITI protocol and the Malmö ITI protocol and would be the preferred 
ITI protocol. All of the three ITI protocols dominate the on-demand strategy, as they have 
both a lower average lifetime cost and higher quality-adjusted life-years (QALYs) gained. The 
cost per QALY gained for the Bonn ITI protocol compared with the Malmö ITI protocol was 
$249,391.84. The cost per QALY gained for the Bonn ITI protocol compared with the low-dose 
ITI protocol was $842,307.69.
Conclusion: The results of data derived from our study suggest that the low-dose ITI protocol 
may be a less expensive and/or more cost-effective option compared with on-demand first-line 
treatment with rFVIIa.
Keywords: cost-utility analysis, immune tolerance induction, on-demand, rFVIIa
Introduction
Hemophilia A is a bleeding disorder caused by a functional absence, or reduced 
levels, of factor VIII (FVIII). In the developed world, prophylaxis for hemophilia 
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A uses infusions of virus-attenuated plasma-derived FVIII 
or recombinant (rFVIII) clotting factor replacement. Such 
  treatment has substantially improved the quality of life (QoL) 
of persons with severe (FVIII . 1%) and moderate (FVIII 
1%–5%) hemophilia A by avoiding bleeding episodes and 
their long-term consequences, particularly in the joints.1 
However, we are still grappling with issues of cost-effective 
care of the disease and its other complications. The most 
serious of these complications is the development of a 
  neutralizing antibody, or inhibitor, to FVIII.
In developed countries, where economic resources 
are available for high-cost products, the development of 
  antibodies neutralizing the hemostatic effect of therapeuti-
cally administered clotting factor concentrates (inhibitors) is 
the key problem of treating hemophilia.2 In the presence of 
an inhibitor, especially if at high titer, the standard safe and 
effective replacement treatment is hampered, and high rates 
of morbidity and mortality are reported.3 In addition, this 
challenging treatment is associated with a very high economic 
burden.4,5 At variance with other settings of chronic disease, 
costs of treatment in hemophilia are mainly related to direct 
costs of replacement clotting factor concentrates.5,6 When 
patients with inhibitors are evaluated, these costs account 
for more than 98% of the strikingly high amount of medical 
and economic resources absorbed for their care.5
Development of inhibitors to transfused FVIII is   currently 
the most severe and challenging complication of hemophilia 
treatment6 and represents the highest economic burden for 
a chronic disease.7 Inhibitors occur in up to one-third of 
patients with severe hemophilia A (FVIII, 1 u/dL).8 The 
presence of an inhibitor complicates treatment and increases 
disease-related morbidity,9 because it renders   factor replace-
ment ineffective.6,10 Consequently, hemophiliacs with 
inhibitors, particularly those with high-titer inhibitors (over 
five Bethesda units), are at increased risk of uncontrollable 
hemorrhage, devastating joint damage, and subsequent 
disability, although they are usually under treatment with 
bypassing agents.10–13
To reduce these risks and improve QoL, immune 
  tolerance induction (ITI), eg, the regular infusion of FVIII 
concentrates over a time period ranging from months to 
years, is usually attempted to overpower high responding 
(anamnesis) FVIII inhibitors of recent onset and restore 
normal factor pharmacokinetics.10,14,15
ITI is nowadays usually started in connection with, or 
early after development of, an inhibitor. The regimen used 
often comprises very high doses of factor concentrate, and 
the treatment course spans over several months or even years. 
Other regimens are also in use with lower doses or combined 
with immunosuppressive agents and extracorporeal inhibitor 
adsorption.16 The high cost of the treatment makes it contro-
versial, and a comparison between two different regimens 
using different dose levels is now ongoing.17
Three primary therapeutic regimens have been developed 
for inhibitor eradication. The high-dose Bonn protocol cur-
rently calls for the administration of FVIII at a dosage of 
150 IU/kg twice daily.18 The Bonn protocol is intensive for 
patients and families and very costly because of high FVIII 
consumption.
In the low-dose Van Creveld (Dutch) regimen, FVIII is 
administered every other day at a dose of 25 IU/kg.19 The 
dose is decreased each time the absolute FVIII   recovery 
exceeds 30%. These reductions are continued until a 
  prophylactic FVIII dose of 10–15 IU/kg three times weekly 
is reached.
The Malmö protocol utilizes extracorporeal immunoad-
sorption with protein A columns as needed to remove high-
titer inhibitory antibodies (over ten Bethesda units).20,21
Two bypassing agents are currently available: the acti-
vated prothrombin complex concentrate (APCC) FEIBA® 
(Baxter AG, Vienna, Austria) and recombinant-activated 
FVII (rFVIIa; NovoSeven®, Novo Nordisk, Bagsværd, 
Denmark). Both products have been shown to control at 
least 80% of bleeding episodes associated with high-titer 
inhibitors, including perioperative bleeding.22–27
rFVIIa was first approved in Europe in 1996. It has proved 
to be an effective and safe therapeutic agent for the manage-
ment of bleeding in hemophiliac patients with inhibitors, 
with adverse thrombotic events occurring in less than 1% 
of patients.28 Data collected in a database demonstrated that 
rFVIIa dosed in a range of less than or equal to 200 µg/kg had 
a bleeding cessation rate of 84% compared with 97% for 
those receiving over 200 µg/kg. The median total dose over 
72 hours was 360 µg/kg (range 40–4280 µg/kg).29
Currently, there are about 7000 hemophilia patients in 
the Islamic Republic of Iran.30 The Iranian national health 
care system allocates more than 31% of total subsidized 
funds on hemophilia. This amounts to $103 million of total 
subsidized. Out of this figure, 38% of this figure is dedi-
cated to hemophilia patients with either inhibitors or FVII 
-deficient patients. In other words, Iran spends $39   million 
for only 450 patients (175 with inhibitors and 276 with 
FVII   deficiency) annually. Average per capita consumption 
of FVIII clotting factor is rising in the country and, in 2010, 
it was about 2.0, but there is a lack of economic evaluation 
studies to measure the cost-effectiveness of this spending.30
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The high initial cost of ITI has led some to question the 
cost-effectiveness of this strategy, and long-term data on the 
costs and efficacy of any individual ITI regimen are sparse.31,32 
We therefore conducted a cost-effectiveness   analysis to 
  determine the optimal strategy for the management of patients 
with inhibitors by estimating the lifetime costs and survival 
for ITI followed by the use of FVIII concentrates, compared 
with a strategy using other hemostatic agents without ITI.
Materials and methods
Our analysis is based on the study of Knight et al,33 which 
evaluated the cost-effectiveness of different treatments for 
hemophilia A with high-responding inhibitors. To adapt 
Knight et al’s results to the Iranian context, a few clinical 
parameters were varied, and cost data were replaced with the 
corresponding Iranian estimates of resource use. The time 
horizon of the analysis was 10 years. The foreign exchange 
rate used in the analysis was 10,620 Iranian Rial = 1US$ 
(May, 2011).
The analysis conducted is a cost-utility analysis, ie, an 
economic evaluation that estimates the cost per quality-
adjusted life-year (QALY) gained from undertaking one 
intervention instead of another.8 The QALY is a potential 
measure of health and is obtained by multiplying the   duration 
of a health state (in years) by a factor representing the 
  quality (“utility”) of that health state. A QALY value of 1 is 
equivalent to a year of “perfect health,” whereas a value of 0 
corresponds to “death.”
Utilities
Because of a lack of suitable Iranian data on the effect of the 
different treatment regimens on health-related QoL of indi-
viduals with hemophilia A with high-responding inhibitors, 
the number of QALYs gained for different strategies were 
derived from Knight et al.33 All input data used in the study 
are reported in Table 1.
Resource use
Management of patients with inhibitors in Iran
APCC and rFVIIa are available for the treatment of these 
patients. APCC (Feiba) is used in doses of 50–100 U/kg/
dose for treatment of bleeds every 12 hours until resolution. 
rFVIIa is given at 90–120 µg/kg per dose every 2 to 4 hours 
until bleeding resolves. ITI is occasionally attempted with 
50–100 U/kg of the appropriate factor concentrate three 
times a week.24
All local costs associated with the administration of 
clotting FVIII during ITI and on-demand with rFVIIa are 
shown in Table 2.
Cost analysis
This study was conducted with the perspective of the Iranian 
Ministry of Health. Due to the unavailability of other medical 
resources unit costs, study was focused on treatment costs 
and excluded outpatient and inpatient costs associated with 
the bleeding episodes. The direct costs ($) included are only 
those related to using clotting factors. The total cost per year 
and per patient was estimated by multiplying the price per unit 
(2011) by the number of units used per year during hospital-
ization and/or outpatient treatment. It has been reported that 
when patients with inhibitors are evaluated, their medication 
costs account for more than 98% of medical and economic 
resources absorbed for their care (Table 3). Gringeri et al5,7 
also reported that clotting factors accounted for 99% of the 
medical cost associated with hemophilia patients. Based on 
this information, indirect costs were not taken into account 
in this analysis.
Sensitivity analysis
One-way sensitivity analyses were performed, varying the 
cost of the clotting factor, the drug dose, and the administra-
tion frequency, to test the robustness of the analysis.
Results
To compare the cost-effectiveness of one treatment over 
another is to calculate the incremental cost-effectiveness 
ratio (ICER). The traditional decision rule is that one treat-
ment should be funded over another when the ICER is better 
than the societal value of a QALY. This is represented by the 
Table  1  Immune  tolerance  induction  and  on-demand  default 
protocols











Low dose 50 U/kg/day 43.0 60 29.1
Malmö 207 U/kg/day 53.3 60 28.1
On-demand 90–120 rFVIIa  
µg/kg/day
92 60 25.1
Abbreviations: pdFVIII, plasma-derived factor VIII; QALy, quality-adjusted life-
year; rFVIIa, recombinant-activated factor VIIa.
Table 2 Cost of hemostatic agent in Iran (May, 2011)
Factor Price per unit ($)
Factor VIII 0.3 per IU
Recombinant factor VIIa 684.0 per mg
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formula ICER = (cost T1 - cost T2)/(QALY T1 - QALY T2). 
Table 4 compares the ICERs between the three ITI protocols 
and the on-demand regimen.
When cost-utility analysis is considered, the on-demand 
protocol has the worst QALYs (25.1), whereas ITI is 
  associated with better values. The Bonn protocol obtains the 
best value (33.0) in this setting, intermediate values being 
expressed by the Malmö (28.1) and the low-dose (29.1) 
protocols. On the whole, the comparison of ICERs (cost 
per QALY) made the low-dose ITI protocol the most cost-
effectiveness approach in a lifetime perspective, followed 
by the Malmö and then by the Bonn protocol.
Comparison of the ICERs (Table 4) between the three ITI 
protocols and the on-demand regimen with rFVIIa shows that 
all three ITI protocols dominate the on-demand regimen with 
rFVIIa. Between the ITI protocols the low-dose ITI protocol 
dominates both the Bonn ITI protocol and the Malmö ITI 
protocols and would be the preferred ITI protocol.
Both the low-dose ITI protocol and the Bonn ITI protocol 
generate more health benefit (more QALYs) than both the 
Malmö ITI protocol and the on-demand protocol with rFVIIa 
but at a different cost.
All of three ITI protocols dominate the on-demand 
strategy, as they have both a lower average lifetime cost and 
higher QALYs gained. The cost per QALY gained for the 
Bonn ITI protocol compared with the Malmö ITI protocol 
was $249,391.84. The cost per QALY gained for the Bonn 
ITI protocol compared with the low-dose ITI protocol was 
$842,307.69.
Sensitivity analyses
The sensitivity analyses performed show that the results 
were sensitive to a number of variables, including the cost 
of the clotting factor, which is a cost driver in this study, 
and the drug dose.
Discussion
The aim of this study was to conduct a cost-effectiveness 
analysis of ITI versus on-demand rFVIIa treatment for 
hemophilia A individuals with high-responding inhibitors in 
an Iranian clinical setting. The results of the current study are 
in compliance with those reported by Kessler and Aledort,31 
Knight et al,33 Lippert et al,34 and Colowick et al.35
Patients with hemophilia and inhibitors are a   challenge 
to treat, requiring high costs over their lifetimes for   effective 
management. The drug acquisition costs of   various   treatment 
options must be considered in the context of patient 
QoL and management of the entire bleeding episodes. 
Well-designed studies are needed to compare recombinant 
and plasma-based agents for the treatment of hemophilia 
patients with   inhibitors. In the meantime, decision makers 
are left to   determine which therapies are most cost-effective 
based on the best i  nformation available. The costs and 
cost  -effectiveness of rFVIIa versus ITI are controversial 
and are primarily   dependent on dosing requirements to 
control bleeds. The total dose used to manage a bleeding 
episode may have profound effects on the overall cost of 
treatment.36
As hemophilia with inhibitors is rare, an individual 
clinician may manage only one or two patients at a time. 
The problem of a small sample size with this rare disease 
population is unavoidable, though these patients may have 
up to 20 bleeds per year and few are lost to follow-up as 
patients usually stay with a hematologist/hemophilia center 
because of the frequent need for care. Thus, using economic 
evaluation to understand the larger impact across a health 
system or country might be helpful in understanding the 
broader cost-effectiveness issues associated with selection 
of a preferred drug treatment strategy.36
Additional studies are needed to determine the impact 
of different treatments on the QoL of hemophilia patients 
with inhibitors. In summary, the future direction of outcome 
assessment for hemophilia with inhibitors will probably focus 
on bleeding time comparisons among available treatments 
and how recurrent joint bleeds affect long-term joint status, 
QoL, and cost-effectiveness.
Perhaps one of the most important observations of 
  inhibitor economics, also demonstrated by several authors, 
Table  4  Incremental  cost-effectiveness  ratios:  comparison 
between all four protocols (cost per quality-adjusted life-year)








Low-dose ITI Dominates Dominates
Bonn ITI Dominates $249,391.84 $842,307.69
Abbreviation: ITI, immune tolerance induction.
Table 3 Cost and benefit of the immune tolerance induction (ITI) 
protocols and on-demand therapy with recombinant factor VIIa
Protocol Average cost of  
managing bleeding  
episodes for 10 years ($)
Quality-adjusted 
life-years
Bonn ITI 5,528,649.60 33.0
Low-dose ITI 2,243,649.60 29.1
Malmö ITI 4,306,629.60 28.1
On-demand 6,205,248.00 25.1
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is that the higher overall costs of treating inhibitor patients 
can be largely attributed to only a small number (1%–2%) of 
patients who use huge amounts of bypassing agents.37,38
To our knowledge, this is the first attempt to undertake 
a cost-effectiveness analysis of ITI versus on-demand treat-
ment for hemophilia A individuals with high-responding 
inhibitors in an Iranian clinical setting.
Our study had a number of limitations mainly due to its 
structure, the wide time horizon, the assumptions made, and 
the data used, some of which were derived from different 
sources. Clinical outcomes were derived from a literature 
review. Therefore, in a further economic evaluation it could 
be interesting to compare clinical effectiveness among 
different alternatives used in an Iranian setting, but data 
on costs and outcomes for different clotting factors would 
need to be collected over a longer period of time. Moreover, 
most published guidelines for pharmacoeconomic evalua-
tions recommend the adoption of a societal perspective.38 
The societal perspective, in addition to direct medical 
costs, includes direct nonmedical costs and potential 
indirect costs.38 However, because it has been reported5,7,39 
that clotting factor concentrates account for 98% of total 
costs, this study only limited the information to the direct 
  medical costs.
In spite of all the limitations of pharmacoeconomic study, 
these instruments have a key role when priorities in resource 
allocation have to be established.37 In fact, they provide deci-
sion makers in the health care system with useful tools to 
make more rational and effective decisions.
In countries with limited resources available to the health 
care sector, a strategy of lower-cost treatment and a holistic 
approach to patient care with cost-effective utilization of 
limited resources provide a viable standard of care, especially 
in the expensive field of hemophilia treatment.35 The current 
study can provide the Iranian Ministry of Health with an 
effective tool to allocate its limited resources on more cost-
effective interventions for hemophilia.
Conclusion
The results of data derived from our study suggest that 
the low-dose ITI protocol may be the most cost-effective 
option compared with on-demand first-line treatment with 
rFVIIa.
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